[1]
|
Davison AS, Jones DM, Ruthven S, et al. Clinical evaluation and treatment of phaeochromocytoma[J]. Ann Clin Biochem, 2018, 55: 34-48. doi: 10.1177/0004563217739931 |
[2]
|
Plouin PF, Amar L, Dekkers OM, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma[J]. Eur J Endocrinol, 2016, 174: G1-G10. http://smartsearch.nstl.gov.cn/paper_detail.html?id=b8fcdf4bab3878a9528c755a4ab7f49a |
[3]
|
Fishbein L. Pheochromocytoma and paraganglioma: genetics, diagnosis, and treatment[J]. Hematol Oncol Clin North Am, 2016, 30: 135-150. doi: 10.1016/j.hoc.2015.09.006 |
[4]
|
Reisch N, Peczkowska M, Januszewicz A, et al. Pheochromocytoma: presentation, diagnosis and treatment[J]. J Hypertens, 2006, 24: 2331-2339. doi: 10.1097/01.hjh.0000251887.01885.54 |
[5]
|
Douma S, Petidis K, Kartali N, et al. Pheochromocytoma presenting as diabetic ketoacidosis[J]. J Diabetes Complications, 2008, 22: 295-296. doi: 10.1016/j.jdiacomp.2007.02.006 |
[6]
|
Martin JF, Martin LN, Yugar-Toledo JC, et al. Coronary emergency and diabetes as manifestations of pheochromocytoma[J]. Int J Cardiol, 2010, 139: e39-e41. doi: 10.1016/j.ijcard.2008.11.025 |
[7]
|
Komada H, Hirota Y, So A, et al. Insulin secretion and insulin sensitivity before and after surgical treatment of pheochromocytoma or paraganglioma[J]. J Clin Endocrinol Metab, 2017, 102: 3400-3405. doi: 10.1210/jc.2017-00357 |
[8]
|
Chen Y, Hodin RA, Pandolfi C, et al. Hypoglycemia after resection of pheochromocytoma[J]. Surgery, 2014, 156: 1404-1409. doi: 10.1016/j.surg.2014.08.020 |
[9]
|
La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients[J]. J Hypertens, 2003, 21: 1703-1707. doi: 10.1097/00004872-200309000-00020 |
[10]
|
Turnbull DM, Johnston DG, Alberti KG, et al. Hormonal and metabolic studies in a patient with a pheochromocytoma[J]. J Clin Endocrinol Metab, 1980, 51: 930-933. doi: 10.1210/jcem-51-4-930 |
[11]
|
Colwell JA. Inhibition of insulin secretion by catecholamines in pheochromocytoma[J]. Ann Intern Med, 1969, 71: 251-256. doi: 10.7326/0003-4819-71-2-251 |
[12]
|
Vance JE, Buchanan KD, O'Hara D, et al. Insulin and glucagon responses in subjects with pheochromocytoma: effect of alpha adrenergic blockade[J]. J Clin Endocrinol Metab, 1969, 29: 911-916. doi: 10.1210/jcem-29-7-911 |
[13]
|
Verberne AJ, Korim WS, Sabetghadam A, et al. Adrenaline: insights into its metabolic roles in hypoglycaemia and diabetes[J]. Br J Pharmacol, 2016, 173: 1425-1437. doi: 10.1111/bph.13458 |
[14]
|
Mesmar B, Poola-Kella S, Malek R. The physiology behind diabetes mellitus in patients with pheochromocytoma: a review of the literature[J]. Endocr Pract, 2017, 23: 999-1005. doi: 10.4158/EP171914.RA |
[15]
|
Wiesner TD, Bluher M, Windgassen M, et al. Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma[J]. J Clin Endocrinol Metab, 2003, 88: 3632-3636. doi: 10.1210/jc.2003-030000 |
[16]
|
Cryer PE. Adrenaline: a physiological metabolic regulatory hormone in humans?[J]. Int J Obes Relat Metab Disord, 1993, 17 Suppl 3: S43-S46; discussion S68. |
[17]
|
Rizza RA, Cryer PE, Haymond MW, et al. Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man[J]. J Clin Invest, 1980, 65: 682-689. doi: 10.1172/JCI109714 |
[18]
|
Beninato T, Kluijfhout WP, Drake FT, et al. Resection of pheochromocytoma improves diabetes mellitus in the majority of patients[J]. Ann Surg Oncol, 2017, 24: 1208-1213. doi: 10.1245/s10434-016-5701-6 |
[19]
|
钟历勇.国际糖尿病联盟第19届世界大会会议纪要及新诊断指南精要解读[J].中国卒中杂志, 2007, 2: 66-67. doi: 10.3969/j.issn.1673-5765.2007.01.017 |